— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — The post CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results appeared first on Bio Tech Winners. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy The post Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy appeared first on Bio Tech Winners. Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare The post Diagnostics Industry Leader… Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. („Dyadic“ or the „Company“) (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute… Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – The post Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv appeared first on Bio Tech Winners. Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Management will also participate in two upcoming healthcare conferences Management will also participate in two upcoming healthcare conferences The post Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 appeared first on Bio Tech Winners. Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
In a recent study published in the Journal of Biomedical Optics, researchers from the Indian Institute of Technology Indore unveiled a groundbreaking advancement—a compact and cost-effective PA sensing instrument designed specifically for biomedical tissue diagnosis. This proof-of-concept study employs low-cost diode laser. It represents a crucial step towards bridging the gap between laboratory research and clinical applications. The newly developed instrument integrates multiple laser diodes within a compact casing, alongside a custom-built pulsed current supply unit. This setup ensures efficient PA excitation, generating precise 25 nanosecond pulses at a frequency of 20 kHz. Subsequent data analysis involved calculating frequency spectra to quantitatively assess tissue properties. The results revealed distinct spectral patterns corresponding to different tissue types. For instance, fibrocystic breast disease exhibited a dominant frequency peak around 1.60 MHz, indicative of increased tissue density due to heightened glandular and stromal…
COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities. The post Bavarian Nordic delivered record financial results in 2023 appeared first on Bio Tech Winners. Bavarian Nordic delivered record financial results in 2023
Wird es schon bald möglich sein, Medizin einfach zu inhalieren? Forscher haben ein potenziell revolutionäres Nanomaterial nun erstmalig erfolgreich am Menschen getestet. Sie schreiben von einem „Wundermaterial“. Tests mit Gesichtsmasken Die Wissenschaftler um Dr. Mark Miller vom Zentrum für Herz-Kreislauf-Wissenschaften der Universität Edinburgh verwendeten für diese erste Studie, die in der Fachzeitschrift Nature veröffentlicht wurde, […] Forscher testen „Wundermaterial“ estmals sicher am Menschen
Bei Orphan Drugs wird das politische Ziel, den Preis am Zusatznutzen auszurichten, erst durch die nachgelagerte reguläre Nutzenbewertung erreicht. Dies zeigt eine aktuelle IQWiG-Auswertung. Um die Entwicklung von Arzneimitteln gegen seltene Leiden (Orphan Drugs) trotz wirtschaftlicher Risiken zu fördern, werden diese in Deutschland bevorzugt behandelt: Neue Orphan Drugs müssen erst dann einen Zusatznutzen gegenüber der zweckmäßigen Vergleichstherapie nachweisen, wenn sie die 30-Millionen-Euro-Jahresumsatzgrenze (bis November 2022: 50 Millionen Euro) überschrei-ten. Vorher gilt ihr Zusatznutzen als belegt, der Gemeinsame Bundesausschuss (G-BA) quantifiziert dann lediglich anhand der (Zulassungs-)Unterlagen das Ausmaß des Zusatznutzens. Ist im Rahmen dieser „eingeschränkten Bewertung“ keine Einordnung in die Kategorien „gering“, „beträchtlich“ oder „erheblich“ möglich, so muss der G-BA dem Wirkstoff immer noch einen „nicht quantifizierbaren“ Zusatznutzen attestieren.Das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) hat nun ausgewertet, welche Auswirkung diese Privilegierung der Orphan Drugs auf die Preise der…
